Compliance with azithromycin versus erythromycin in the setting of a pertussis outbreak

American Journal of the Medical Sciences

Volumn 337, Issue 3, 2009, Pages 176-178

  Devasia, Rose A ^a,b,d   Jones, Timothy F ^a   Collier, Beth ^c   Schaffner, William ^d  

^a TENNESSEE DEPARTMENT OF HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Mid Cumberland Regional Health Department   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Azithromycin; Erythromycin; Pertussis

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; ERYTHROMYCIN;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PATIENT COMPLIANCE; PERTUSSIS; PRESCHOOL CHILD; PROPHYLAXIS; QUESTIONNAIRE; SCHOOL CHILD; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; CASE CONTROL STUDY; COMPARATIVE STUDY; EPIDEMIC;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; WHOOPING COUGH;

EID: 63249118395     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318184e72f     Document Type: Article

References (13)

1. Centers for Disease Control and Prevention (CDC). Pertussis - United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002;51:73-76
2. Centers for Disease Control and Prevention (CDC). School-associated pertussis outbreak - Yavapai County, Arizona, September 2002-February 2003. MMWR Morb Mortal Wkly Rep 2004;53:216-219
3. Centers for Disease Control and Prevention (CDC). Pertussis out-break - Vermont, 1996. MMWR Morb Mortal Wkly Rep 1997;46:822-826
4. Centers for Disease Control and Prevention (CDC). Pertussis outbreak among adults at an oil refinery - Illinois, August-October 2002. MMWR Morb Mortal Wkly Rep 2003;52:1-4.
5. Centers for Disease Control and Prevention (CDC). Pertussis deaths - United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:616-618
6. Langley JM, Halperin SA, Boucher FD, et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004;114:e96-e101.
7. Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J 2001;20:1149-1154 (Pubitemid 34016428)
8. Tiwari T, Murphy TV, Moran J. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005;54:1-16.
9. Martinez SM, Kemper CA, Haiduven D, et al. Azithromycin prophylaxis during a hospitalwide outbreak of a pertussis-like illness. Infect Control Hosp Epidemiol 2001;22:781-783 (Pubitemid 34157721)
10. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-1096 (Pubitemid 39167513)
11. Shaffer D, Singer S, Korvick J, et al. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200. (Pubitemid 34753906)
12. Cooper WO, Griffin MR, Arbogast P, et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002;156:647-650 (Pubitemid 34755991)
13. Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999;354:2101-2105